[{"orgOrder":0,"company":"SonALAsense","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SonALAsense","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"SonALAsense \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SonALAsense \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by SonALAsense

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : SONALA-001 (aminolevulinic acid) is a porphyrin precursor and optical imaging agent. The mechanism of action of aminolevulinic acid is as a fluorescence contrast activity.

                          Product Name : SONALA-001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 03, 2023

                          Lead Product(s) : Aminolevulinic Acid HCl

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank